Cargando…
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial
IMPORTANCE: Many patients with generalized myasthenia gravis (gMG) have substantial clinical disability, persistent disease burden, and adverse effects attributable to chronic immunosuppression. Therefore, there is a significant need for targeted, well-tolerated therapies with the potential to impro...
Ejemplares similares
-
Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study
por: McPherson, Tarrant, et al.
Publicado: (2020) -
Cross‐sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment
por: Cutter, Gary, et al.
Publicado: (2019) -
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
por: Tang, Guo-Qing, et al.
Publicado: (2023) -
Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
por: Tang, Guo-Qing, et al.
Publicado: (2023) -
Climate‐driven shifts in leaf senescence are greater for boreal species than temperate species in the Acadian Forest region in contrast to leaf emergence shifts
por: Spafford, Lynsay, et al.
Publicado: (2023)